v3.25.2
Unaudited Condensed Consolidated Statements of Changes in Equity - USD ($)
Common Stock
Class A
Common Stock
Class B
Common Stock
DiamiR Biosciences Corp
Additional Paid-in Capital Amount
DiamiR Biosciences Corp
Additional Paid-in Capital Amount
Accumulated deficit Amount
DiamiR Biosciences Corp
Accumulated deficit Amount
Accumulated Other Comprehensive (loss) income Amount
Non- controlling interests Amount
DiamiR Biosciences Corp
Total
Balance at Dec. 31, 2021 $ 13,202,408 $ 22,437,754     $ 43,506,717   $ (55,537,515) $ (2,019) $ (6,101,223)   $ 17,506,122
Balance (in Shares) at Dec. 31, 2021 1,320,241 2,243,776                  
Issuance of shares to non-controlling interest     52,024   (52,024)  
Share-based compensation     1,646,999     1,646,999
Conversion of Class B Ordinary Shares to Class A Ordinary Shares                    
Exercise of share options $ 67,120     102,340     169,460
Exercise of share options (in Shares) 6,712                  
Exchange difference on translation of foreign operations       35,826   35,826
Net loss       (9,799,560) (1,725,542)   (11,525,102)
Balance at Dec. 31, 2022 $ 13,269,528 $ 22,437,754     45,308,080   (65,337,075) 33,807 (7,878,789)   7,833,305
Balance (in Shares) at Dec. 31, 2022 1,326,953 2,243,776                  
Issuance of shares to non-controlling interest     67,766   (67,766)  
Issuance of shares in exchange of share options and settlement of liabilities $ 1     3,078,195     3,078,196
Issuance of shares in exchange of share options and settlement of liabilities (in Shares) 70,430                  
Issuance of shares for share-based compensation $ 1     176,263     176,264
Issuance of shares for share-based compensation (in Shares) 65,770                  
Placing of Class A Ordinary Shares $ 2     1,575,560     1,575,562
Placing of Class A Ordinary Shares (in Shares) 215,959                  
Share-based compensation     1,088,925     1,088,925
Conversion of convertible notes $ 13     5,999,987     6,000,000
Conversion of convertible notes (in Shares) 1,250,000                  
Conversion of Class B Ordinary Shares to Class A Ordinary Shares                     6,000,000
Exercise of share options         16,506     16,506
Exercise of share options (in Shares) 791                  
Rounding up for reverse stock split (in Shares) 8,018                  
Exchange difference on translation of foreign operations       (44,430)   (44,430)
Net loss       (2,824,647) (1,516,328)   (4,340,975)
Balance at Dec. 31, 2023 $ 31 $ 22     93,018,528   (68,161,722) (10,623) (9,462,883)   15,383,353
Balance (in Shares) at Dec. 31, 2023 2,937,921 2,243,776                  
Adjustment for change of par value $ (13,269,514) $ (22,437,732)     35,707,246    
Balance at May. 31, 2023     $ 4,441 $ 4,440,256   $ (4,464,931)       $ (20,234)  
Balance (in Shares) at May. 31, 2023     4,440,891                
Share-based compensation       194,846           194,846  
Net loss       (614,405)       (614,405)  
Balance at May. 31, 2024     $ 4,441 4,670,165   (5,079,336)       (404,730)  
Balance (in Shares) at May. 31, 2024     4,440,891                
Discount on note payable to founder       35,063           35,063  
Balance at Dec. 31, 2023 $ 31 $ 22     93,018,528   (68,161,722) (10,623) (9,462,883)   15,383,353
Balance (in Shares) at Dec. 31, 2023 2,937,921 2,243,776                  
Conversion of Class B Ordinary Shares to Class A Ordinary Shares $ 4 $ (4)        
Conversion of Class B Ordinary Shares to Class A Ordinary Shares (in Shares) 446,842 (446,842)                  
Exercise of share options $ 2     451,658     451,660
Exercise of share options (in Shares) 289,401                  
Exchange difference on translation of foreign operations       861   861
Net loss       (2,643,796) (15,091)   (2,658,887)
Balance at Jun. 30, 2024 $ 37 $ 18     93,470,186   (70,805,518) (9,762) (9,477,974)   13,176,987
Balance (in Shares) at Jun. 30, 2024 3,674,164 1,796,934                  
Balance at Dec. 31, 2023 $ 31 $ 22     93,018,528   (68,161,722) (10,623) (9,462,883)   15,383,353
Balance (in Shares) at Dec. 31, 2023 2,937,921 2,243,776                  
Conversion of Class B Ordinary Shares to Class A Ordinary Shares $ 4 $ (4)        
Conversion of Class B Ordinary Shares to Class A Ordinary Shares (in Shares) 446,842 (446,842)                  
Exercise of share options $ 2     451,658     451,660
Exercise of share options (in Shares) 427,060                  
Exchange difference on translation of foreign operations         99,785   99,785
Disposal of NCI         4,639       (4,639)  
Net loss       (4,267,806) 110,069   (4,157,737)
Balance at Dec. 31, 2024 $ 37 $ 18     93,474,825   (72,429,528) 89,162 (9,357,453)   11,777,061
Balance (in Shares) at Dec. 31, 2024 3,811,823 1,796,934                  
Balance at May. 31, 2024     $ 4,441 4,670,165   (5,079,336)       (404,730)  
Balance (in Shares) at May. 31, 2024     4,440,891                
Share-based compensation       24,312           24,312  
Net loss       (743,235)       (743,235)  
Balance at May. 31, 2025     $ 4,441 4,729,169   $ (5,822,571)       (1,088,961)  
Balance (in Shares) at May. 31, 2025     4,440,891                
Discount on note payable to founder       $ 34,692           $ 34,692  
Balance at Dec. 31, 2024 $ 37 $ 18     93,474,825   (72,429,528) 89,162 (9,357,453)   11,777,061
Balance (in Shares) at Dec. 31, 2024 3,811,823 1,796,934                  
Placing of Class A Ordinary Shares $ 15     2,699,185     2,699,200
Placing of Class A Ordinary Shares (in Shares) 1,535,000                  
Exchange difference on translation of foreign operations       (258,322)   (258,322)
Net loss       (441,780) (7,515)   (449,295)
Balance at Jun. 30, 2025 $ 52 $ 18     $ 96,174,010   $ (72,871,308) $ (169,160) $ (9,364,968)   $ 13,768,644
Balance (in Shares) at Jun. 30, 2025 5,346,823 1,796,934